Business
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCLCRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. (\"Citius Oncology\") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. (\"Citius Pharma\") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) has been selected for poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 29 – June 2, 2026, in Chicago, Illinois.The abstract, submitted by investigators at the University of Pittsburgh Medical Center, was selected for presentation from more than 8,500 submissions reviewed by the ASCO Scientific Program Committee. The full abstract was made available on May 21, 2026, via the American Society of Clinical Oncology website.\"We are pleased to see this investigator-sponsored study selected for presentation at ASCO, reflecting continued clinical interest in denileukin diftitox-cxdl across multiple tumor types,\" said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. \"We look forward to engaging with the clinical oncology community to discuss the encouraging topline Phase 1 data evaluating Treg cell suppression in combination with checkpoint inhibitors.\"Abstract Details:Abstract Number: 2564Title: Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study resultsSession Type: Poster Session – Developmental Therapeutics—ImmunotherapyPoster Board: 354Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT The Phase 1 study evaluated the safety, tolerability, and preliminary activity of denileukin diftitox-cxdl in combination with pembrolizumab in patients with relapsed or refractory gynecologic malignancies.The ASCO...